This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - human growth hormone in children with growth failure

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE has made the following recommendations about the use of human growth hormone (somatropin) in children:

  • somatropin (recombinant human growth hormone) is recommended as a treatment option for children with growth failure associated with any of the following conditions:
    • growth hormone deficiency
    • Turner syndrome
    • Prader-Willi syndrome
    • chronic renal insufficiency
    • born small for gestational age with subsequent growth failure at 4 years of age or later
    • short stature homeobox-containing gene (SHOX) deficiency
  • treatment with somatropin should always be initiated and monitored by a paediatrician with specialist expertise in managing growth hormone disorders in children. The choice of product should be made on an individual basis after informed discussion between the responsible clinician and the patient and/or their carer about the advantages and disadvantages of the products available, taking into consideration therapeutic need and the likelihood of adherence to treatment. If, after that discussion, more than one product is suitable, the least costly product should be chosen
  • treatment with somatropin should be discontinued if any of the following apply:
    • growth velocity increases less than 50% from baseline in the first year of treatment
    • final height is approached and growth velocity is less than 2 cm total growth in 1 year
    • there are insurmountable problems with adherence
    • final height is attained
  • in Prader-Willi syndrome evaluation of response to therapy should also consider body composition. Treatment should not be discontinued by default. The decision to stop treatment should be made in consultation with the patient and/or carers either by:
    • a paediatrician with specialist expertise in managing growth hormone disorders in children, or
    • an adult endocrinologist, if care of the patient has been transferred from paediatric to adult services

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.